drugset
drugset / Trial / NCT03722576

Vidofludimus Calcium for Primary Sclerosing Cholangitis

NCT03722576 ↗

Phase 2 Completed 18 enrolled Elizabeth Carey Arizona State University · collab
NaSingle-groupOpen-labelTreatment

Summary

To examine the safety, tolerability, and efficacy of daily dosing with vidofludimus calcium over a 6-month period.

Timeline

Start
2019-06-17
Primary completion
2020-06-30
Completion
2020-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Vidofludimus Small molecule 30 mg Oral

Indications

primary sclerosing cholangitis